NCT07199335 - Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

HIVSubstance Use Disorder (SUD)Injection Drug Use

Interventions

DRUG

APRETUDE (cabotegravir)

All participants will be prescribed APRETUDE based on APRETUDE's FDA approved indication, which is sexual risk of HIV transmission.

Trial Locations (2)

Massachusetts General Hospital, Boston

Fenway Health, Boston